⌕
MapLight Therapeutics · MPLT · Nasdaq
Tenet 74 · Solid
Compare
$6.90−4.83%At closeTenet 74 · Solid
$6.90−0.35 (−4.83%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

MapLight Therapeutics (MPLT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is MPLT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireNov 16, 2026 · 07:15 ETCOMPANY'S OWN WORDS
MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in 2028…

MPLT −4.8% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 16:05 ETCOMPANY'S OWN WORDS
MapLight Therapeutics to Participate in Upcoming Investor Conference

SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference: Event: 202…

MPLT −4.8% todayRead at source ↗
● Defense WorldOct 19, 2026 · 04:52 ET
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $124,068.40 in Stock

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider Erin Pennock Foff sold 15,355 shares of the company's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $8…

MPLT −4.8% todayRead at source ↗
● Defense WorldOct 19, 2026 · 04:52 ET
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $96,024.32 in Stock

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider Anatol Kreitzer sold 12,248 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $7.84, for a t…

MPLT −4.8% todayRead at source ↗
● Defense WorldOct 19, 2026 · 04:52 ET
Maplight Therapeutics (NASDAQ:MPLT) CFO Sells $82,149.36 in Stock

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) CFO Jonathan Gillis sold 10,167 shares of Maplight Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold at an average price o…

MPLT −4.8% todayRead at source ↗
● Defense WorldOct 19, 2026 · 04:52 ET
Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $93,025.04 in Stock

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider James Lillie sold 11,513 shares of Maplight Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold at an average price …

MPLT −4.8% todayRead at source ↗
● Zacks Investment ResearchOct 16, 2026 · 10:35 ET
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)

The heavy selling pressure might have exhausted for MapLight Therapeutics, Inc. (MPLT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in…

MPLT −4.8% todayRead at source ↗
● Defense WorldOct 16, 2026 · 02:59 ET
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Stock Has Consensus Price Target of $29.50

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) has received a consensus rating of "Moderate Buy" from the eighteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated th…

MPLT −4.8% todayRead at source ↗
● Zacks Investment ResearchOct 14, 2026 · 10:36 ET
Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround

MapLight Therapeutics, Inc. (MPLT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e…

MPLT −4.8% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 07:00 ETCOMPANY'S OWN WORDS
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

Award honors foundational discoveries in optogenetics and circuit mapping These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight's circuit-based approach to drug discovery SAN FRA…

MPLT −4.8% todayRead at source ↗
● GlobeNewsWireSep 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
MapLight Therapeutics to Participate in Upcoming Investor Conference

SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:…

MPLT −4.8% todayRead at source ↗
● Defense WorldSep 2, 2026 · 03:52 ET
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT

BlackRock Inc. acquired a new position in shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT) in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The instituti…

MPLT −4.8% todayRead at source ↗

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just MPLT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.